Public Employees Retirement System of Ohio Boosts Stake in Amgen Inc. $AMGN

Public Employees Retirement System of Ohio lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 221,647 shares of the medical research company’s stock after buying an additional 2,766 shares during the period. Public Employees Retirement System of Ohio’s holdings in Amgen were worth $77,986,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FCA Corp TX grew its stake in Amgen by 2.1% during the 1st quarter. FCA Corp TX now owns 18,432 shares of the medical research company’s stock valued at $6,485,000 after purchasing an additional 376 shares during the last quarter. Compound Planning Inc. raised its stake in shares of Amgen by 83.4% in the first quarter. Compound Planning Inc. now owns 17,195 shares of the medical research company’s stock worth $6,050,000 after purchasing an additional 7,818 shares during the last quarter. Klingman & Associates LLC lifted its holdings in shares of Amgen by 3.5% during the first quarter. Klingman & Associates LLC now owns 2,097 shares of the medical research company’s stock worth $738,000 after purchasing an additional 71 shares during the period. Modern Wealth Management LLC lifted its holdings in shares of Amgen by 3.5% during the first quarter. Modern Wealth Management LLC now owns 5,723 shares of the medical research company’s stock worth $2,022,000 after purchasing an additional 192 shares during the period. Finally, Keebeck Wealth Management boosted its position in Amgen by 28.9% in the first quarter. Keebeck Wealth Management now owns 2,431 shares of the medical research company’s stock valued at $855,000 after buying an additional 545 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 1.5%

Amgen stock opened at $371.50 on Friday. The business’s 50-day moving average price is $350.28 and its 200 day moving average price is $351.63. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market cap of $200.50 billion, a price-to-earnings ratio of 25.85, a price-to-earnings-growth ratio of 3.70 and a beta of 0.41. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the company posted $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. UBS Group increased their price target on shares of Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday, June 12th. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 price objective on shares of Amgen in a research note on Wednesday, July 1st. Finally, Truist Financial raised their target price on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $356.62.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.